Founded in 1990, TUL is one of China’s leading integrated pharmaceutical companies, principally engaged in the R&D, manufacturing, and sales of pharmaceutical products. The company was listed on the Hong Kong Stock Exchange on June 15, 2007 (Stock Code: 3933.HK). With over 30 years of development, TUL has established four major business segments: finished products, APIs, biopharmaceuticals, and animal healthcare. It has built production and R&D entities across Hong Kong, Zhuhai, Zhongshan, Jiangmen, Bayannur, Hengqin, and Ningbo. Its product portfolio covers intermediate products, bulk medicines, finished products, animal health products, comprehensive health products, and medical devices. Its sales network spans the globe, with a workforce of over 17,000 employees.